Active Biotech Appoints Erik Vahtola as Chief Medical Officer
January 4, 2022
News
First subject dosed in phase I clinical study with eye-drop formulation of laquinimod
December 10, 2021
Data on naptumomab estafenatox enhancing CAR-T cells potency presented by Active Biotech’s partner NeoTX at SITC 2021
November 24, 2021
Active Biotech’s partner NeoTX to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 9, 2021
New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)
November 4, 2021
Active Biotech’s partner NeoTX will host KOL webinar on overcoming check point Inhibitor resistance
July 8, 2021
Active Biotech’s presentation at “Aktiedagen” May 4, 2021 (Swedish shareholders’ association, in Swedish)
May 4, 2021
Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab
April 19, 2021
Active Biotech enters into a manufacturing agreement with Famar Health Care Services for new formulation of Laquinimod
February 4, 2021
Adjustment of period for trading in subscription rights and interim shares in Active Biotech’s rights issue
January 7, 2021
Active Biotech publishes prospectus and certain new financial information included in the prospectus
January 5, 2021
Report from extraordinary general meeting in Active Biotech and adjustment of previously communicated timetable for the rights issue
November 30, 2020